Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers

International Journal of Oncology

Volumn 28, Issue 5, 2006, Pages 1113-1119

  Connell, Philip P ^a   Jayathilaka, Krishanthi ^a   Haraf, Daniel J ^a   Weichselbaum, Ralph R ^a   Vokes, Everett E ^a   Lingen, Mark W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

DNA repair; Head and neck tumors; Homologous recombination; Molecular markers; RAD51

Indexed keywords

ANTINEOPLASTIC AGENT; RAD51 PROTEIN;

AGED; ARTICLE; DNA REPAIR; FEMALE; GENETICS; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; DNA REPAIR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RAD51 RECOMBINASE; RETROSPECTIVE STUDIES;

EID: 33646830972     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.5.1113     Document Type: Article

References (36)

1. Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M, Liu N, Legerski RJ and Thompson LH: Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci USA 92: 6354-6358, 1995.
2. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, Brookman KW, Siciliano MJ, Walter CA, Fan W, Narayana LS, Zhou ZQ, Adamson AW, Sorensen KJ, Chen DJ, Jones NJ and Thompson LH: XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1: 783-793, 1998.
3. Godthelp BC, Wiegant WW, van Duijn-Goedhart A, Scharer OD, van Buul PP, Kanaar R and Zdzienicka MZ: Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res 30: 2172-2182, 2002.
4. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, Thompson LH and Takeda S: Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21: 2858-2866, 2001.
5. Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R and Panasci LC: In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst 93: 1473-1478, 2001.
6. Xia SJ, Shammas MA and Shmookler Reis RJ: Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 17: 7151-7158, 1997.
7. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S and Haaf T: Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62: 219-225, 2002.
8. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN and Helleday T: The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 105: 472-479, 2003.
9. Vispe S, Cazaux C, Lesca C and Defais M: Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 26: 2859-2864, 1998.
10. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R and Skorski T: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8: 795-806, 2001.
11. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R and Skorski T: Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22: 4189-4201, 2002.
12. Bello VE, Aloyz RS, Christodoulopoulos G and Panasci LC: Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 63: 1585-1588, 2002.
13. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H and Sturzbecher HW: DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19: 2791-2795, 2000.
14. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, Feller AC, Lopens A, Diedrich K, Schwinger E and Sturzbecher HW: Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88: 907-913, 2000.
15. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB and von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62: 2890-2896, 2002.
16. Henning W and Sturzbecher HW: Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193: 91-109, 2003.
17. Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, Yamauchi A, Inamoto T, Ko K, Yazumi S, Motoda H, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y and Takahashi R: Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 88: 28-36, 2000.
18. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S and Stuerzbecher HW: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93: 137-143, 2005.
19. Brockstein B and Vokes EE: Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol 31: 786-193, 2004.
20. Lingen MW, Chang KW, McMurray SJ, Solt DB, Kies MS, Mittal BB, Haines GK and Pelzer HJ: Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck 22: 328-335, 2000.
21. Schliephake H: Prognostic relevance of molecular markers of oral cancer - a review. Int J Oral Maxillofac Surg 32: 233-245, 2003.
22. Koch W and Sidransky D: Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma. Semin Radiat Oncol 14: 130-138, 2004.
23. Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, Henning W, Pedeux R, Wang XW, Hofseth LJ, Yang Q, Garfield SH, Sturzbecher HW and Harris CC: p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 63: 2596-2605, 2003.
24. Yun S, Lie ACC and Porter AC: Discriminatory suppression of homologous recombination by p53. Nucleic Acids Res 32: 6479-6489, 2004.
25. Maacke H, Hundertmark C, Miska S, Voss M, Kalthoff H and Sturzbecher HW: Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol 128: 219-222, 2002.
26. Raderschall E, Bazarov A, Cao J, Lurz R, Smith A, Mann W, Ropers HH, Sedivy JM, Golub EI, Fritz E and Haaf T: Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. J Cell Sci 115: 153-164, 2002.
27. Flygare J, Benson F and Hellgren D: Expression of the human RAD51 gene during the cell cycle in primary human peripheral blood lymphocytes. Biochim Biophys Acta 1312: 231-236, 1996.
28. Yamamoto A, Taki T, Yagi H, Habu T, Yoshida K, Yoshimura Y, Yamamoto K, Matsushiro A, Nishimune Y and Morita T: Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet 251: 1-12, 1996.
29. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K and Tofilon PJ: Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63: 7377-7383, 2003.
30. Sturzbecher HW, Donzelmann B, Henning W, Knippschild U and Buchhop S: p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 15: 1992-2002, 1996.
31. Buchhop S, Gibson MK, Wang XW, Wagner P, Sturzbecher HW and Harris CC: Interaction of p53 with the human Rad51 protein. Nucleic Acids Res 25: 3868-3874, 1997.
32. Connell PP, Siddiqui N, Hoffman S, Kuang A, Khatipov EA, Weichselbaum RR and Bishop DK: A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin. Cancer Res 64: 3002-3005, 2004.
33. Ohnishi T, Taki T, Hiraga S, Arita N and Morita T: In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 245: 319-324, 1998.
34. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K and Kaneda Y: Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7: 1044-1052, 2005.
35. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH and Margison GP: Ribozyme minigene-mediated RAD51 downregulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 29: 1534-1538, 2001.
36. Chen CF, Chen PL, Zhong Q, Sharp ZD and Lee WH: Expression of BRC repeats in breast cancer cells disrupts the BRCA2- Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control. J Biol Chem 274: 32931-32935, 1999.